Literature DB >> 21207029

A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery.

Wei-Yu Kao1, Chien-Wei Su, Gar-Yang Chau, Wing-Yiu Lui, Chew-Wun Wu, Jaw-Ching Wu.   

Abstract

BACKGROUND: The impact of viral factors on the prognosis of hepatocellular carcinoma (HCC) remains controversial because of heterogeneous populations included in previous reports. This study aims to compare clinicopathologic features and prognoses between patients with hepatitis B- and hepatitis C-related HCC who underwent resection surgery.
METHODS: We enrolled 609 patients with positive serum hepatitis B virus (HBV) surface antigen (HBsAg) and negative serum antibody against hepatitis C virus (anti-HCV) as the B-HCC group and 206 patients with negative serum HBsAg and positive anti-HCV as the C-HCC group. The overall survival rates and cumulative recurrence rates were compared between these two groups.
RESULTS: B-HCC patients were significantly younger, predominantly male, had better liver functional reserve, but more advanced tumor stage than C-HCC patients. After a median follow-up period of 40.6 months, 427 patients had died. Furthermore, 501 patients had tumor recurrence after surgery. The postoperative overall survival rates (p = 0.640) and recurrence rates (p = 0.387) of the two groups were comparable. However, the overall survival rate was higher in the B-HCC group than in the C-HCC group in the cases of transplantable HCC (p = 0.021) and Barcelona-Clinic Liver Cancer stage A HCC (p = 0.040).
CONCLUSIONS: Viral etiologies were not apparent in determining outcomes of HCC patients who underwent resection due to heterogeneous studied populations. In early-stage HCC, B-HCC patients had better outcomes than C-HCC patients did because of better liver reserve and less hepatic inflammation.

Entities:  

Mesh:

Year:  2011        PMID: 21207029     DOI: 10.1007/s00268-010-0928-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  31 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

3.  Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma.

Authors:  Hung-Hsu Hung; Chien-Wei Su; Chiung-Ru Lai; Gar-Yang Chau; Che-Chang Chan; Yi-Hsiang Huang; Teh-Ia Huo; Pui-Ching Lee; Wei-Yu Kao; Shou-Dong Lee; Jaw-Ching Wu
Journal:  Hepatol Int       Date:  2010-09-24       Impact factor: 6.047

4.  Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients.

Authors:  Chien-Hung Chen; Ting-Tsung Chang; Ken-Sheng Cheng; Wei-Wen Su; Sheng-Shun Yang; Hans Hsienhong Lin; Shun-Sheng Wu; Chuan-Mo Lee; Chi-Sin Changchien; Chien-Jen Chen; Jin-Chuan Sheu; Ding-Shinn Chen; Sheng-Nan Lu
Journal:  Liver Int       Date:  2006-09       Impact factor: 5.828

5.  Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience.

Authors:  S Roayaie; M B Haim; S Emre; T M Fishbein; P A Sheiner; C M Miller; M E Schwartz
Journal:  Ann Surg Oncol       Date:  2000-12       Impact factor: 5.344

6.  Differences in long-term outcome and prognostic factors according to viral status in patients with hepatocellular carcinoma treated by surgery.

Authors:  Kazuhiro Kondo; Kazuo Chijiiwa; Mayumi Funagayama; Masahiro Kai; Kazuhiro Otani; Jiro Ohuchida
Journal:  J Gastrointest Surg       Date:  2007-11-13       Impact factor: 3.452

7.  Etiology-dependent molecular mechanisms in human hepatocarcinogenesis.

Authors:  Christof Schlaeger; Thomas Longerich; Claudia Schiller; Peter Bewerunge; Arianeb Mehrabi; Grischa Toedt; Jörg Kleeff; Volker Ehemann; Roland Eils; Peter Lichter; Peter Schirmacher; Bernhard Radlwimmer
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

8.  Comparison of surgical outcomes for small hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Chinese experience.

Authors:  Qiang Li; Huikai Li; Yu Qin; P Peter Wang; Xishan Hao
Journal:  J Gastroenterol Hepatol       Date:  2007-11       Impact factor: 4.029

Review 9.  Novel advancements in the management of hepatocellular carcinoma in 2008.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  J Hepatol       Date:  2008-02-12       Impact factor: 25.083

Review 10.  Hepatitis C virus-induced hepatocarcinogenesis.

Authors:  Birke Bartosch; Robert Thimme; Hubert E Blum; Fabien Zoulim
Journal:  J Hepatol       Date:  2009-05-23       Impact factor: 25.083

View more
  34 in total

1.  Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008.

Authors:  Sean F Altekruse; Katherine A McGlynn; Lois A Dickie; David E Kleiner
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

2.  Model based on γ-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis.

Authors:  Xin-Sen Xu; Yong Wan; Si-Dong Song; Wei Chen; Run-Chen Miao; Yan-Yan Zhou; Ling-Qiang Zhang; Kai Qu; Si-Nan Liu; Yue-Lang Zhang; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system.

Authors:  Albert C Y Chan; Sheung Tat Fan; Ronnie T P Poon; Tan To Cheung; Kenneth S H Chok; See Ching Chan; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2012-12-02       Impact factor: 3.647

4.  Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma.

Authors:  Yuan Hong; Yibing Peng; Z Sheng Guo; Jose Guevara-Patino; Junfeng Pang; Lisa H Butterfield; Nahid F Mivechi; David H Munn; David L Bartlett; Yukai He
Journal:  Hepatology       Date:  2014-02-18       Impact factor: 17.425

5.  Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection.

Authors:  Hung-Hsu Hung; Hao-Jan Lei; Gar-Yang Chau; Chien-Wei Su; Cheng-Yuan Hsia; Wei-Yu Kao; Wing-Yiu Lui; Wen-Chieh Wu; Han-Chieh Lin; Jaw-Ching Wu
Journal:  J Gastrointest Surg       Date:  2012-12-06       Impact factor: 3.452

6.  Emerging trends in hepatocellular carcinoma incidence and mortality.

Authors:  Basile Njei; Yaron Rotman; Ivo Ditah; Joseph K Lim
Journal:  Hepatology       Date:  2014-11-24       Impact factor: 17.425

Review 7.  Surgical approach for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Junichi Shindoh; Masaji Hashimoto; Goro Watanabe
Journal:  World J Hepatol       Date:  2015-01-27

Review 8.  Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.

Authors:  Yukai He; Yuan Hong; Gerald J Mizejewski
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

9.  Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy.

Authors:  Jianguo Zhou; Tao Yan; Xinyu Bi; Hong Zhao; Zhen Huang; Yefan Zhang; Yuan Li; Li Feng; Jing Wang; Jianqiang Cai
Journal:  Tumour Biol       Date:  2013-01-16

10.  Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma.

Authors:  Zheng Li; Zhengqing Lei; Yong Xia; Jun Li; Kui Wang; Han Zhang; Xuying Wan; Tian Yang; Weiping Zhou; Mengchao Wu; Timothy M Pawlik; Wan Yee Lau; Feng Shen
Journal:  JAMA Surg       Date:  2018-10-17       Impact factor: 14.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.